• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

What the Debt Ceiling Deal Could Mean for Imaging

Article

For the first stage of cuts, which calls for an immediate $1 trillion over a decade in exchange for raising the debt ceiling by an additional $900 billion, imaging reimbursement was spared. But that might not be the case for the second stage, according to ACR.

President Obama and congressional lawmakers have agreed on major spending cuts as a part of the debt ceiling deal aimed at staving off a financial default.

The cuts are to happen in two stages. For the first stage, which calls for an immediate $1 trillion over a decade in exchange for raising the debt ceiling by an additional $900 billion, imaging reimbursement was spared. But that might not be the case for the second stage, according to ACR.

The second round of $1.4 to $1.5 trillion in cuts will be identified by a bipartisan “super committee” of House and Senate members. The group is expected to submit its recommendations at the end of November, and those recommendations could include cuts to Medicare, notes Aubrey Westgate at DI's sister publication, Physicians Practice.

“Although successful in averting any cuts associated with the initial $900 billion debt ceiling increase, ACR anticipates that the 12-member super committee undoubtedly will consider changes in Medicare physician reimbursement rates to cut costs,” according to the ACR. “Cuts to imaging will likely be part of a larger package of physician reimbursement reductions.”

If the committee doesn’t reach an agreement, $1.2 trillion in automatic cuts would be applied across the board, and Medicare would be included.

ACR vowed to continue educating lawmakers about “why further cuts to imaging are unnecessary and will adversely impact patient care.”

Have you been following the debt ceiling debate? Are you concerned it could impact imaging? Tell us what you think.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.